AxioMx, Inc. (Branford, CT). Sold to abcam Plc in November of 2015, the company’s technology platform permits the rapid development and production of custom monoclonal antibodies that are highly specific, have high affinity, and are optimized to work in customer-specified applications. The technical team previously anchored the scientific development efforts of Affomix Corporation, which Elm Street Ventures co-founded in 2006 and which was sold to Illumina in 2010. ESV invested in the seed financing alongside management and Connecticut Innovations, and lead the Series A financing. AxioMx was co-founded by Chris McLeod, now an Elm Street partner. Elm Street was represented on the board by Rob Bettigole.